1.Application of low molecular weight heparins (LMWH) has been proven to be beneficial for the prevention of VTE in ischemic stroke patients.
对于缺血性卒中患者，使用低分子肝素已经证明可以有效预防VTE。
2.Low-molecular-weight heparins are safe and effective for outpatient treatment of deep vein thrombosis (DVT).
低分子量肝素是安全有效的门诊治疗深静脉血栓形成（DVT）。
3.Low-molecular-weight heparins are now replacing unfractionated heparin for the treatment of DVT and PTE in pregnancy.
低分子量肝素现在取代普通肝素治疗深静脉血栓和新加坡在怀孕。
4.Rudiment clinical observation of the application of low-molecular-weight heparins in percutaneous coronary intervention
低分子肝素在经皮冠状动脉成形术中的应用
5.Clinical study of low molecular weight heparins in treatment of chronic pulmonary heart diseases
低分子肝素治疗慢性肺源性心脏病合并高凝状态的临床研究
6.Detection of thrombus precursor protein in severe sepsis and intervention therapy of low molecular weight heparins and low dose of urokinase
血栓前体蛋白测定在严重脓毒症中的意义及干预治疗对其的影响
7.Mechanism of inhibiting rat glomerular mesangial cells proliferation by low-molecular-weight heparins
低分子肝素抑制肾小球系膜细胞增生机制的研究
8.The efficacy observation of low-molecular weight heparins therapy for acute coronary syndrome with non-ST-segment elevation
低分子肝素治疗非ST段抬高急性冠状动脉综合征的疗效
9.Comparative studies on influences of three heparins on maintenance hemodialysis patients
三种肝素对维持性血液透析患者相关指标的影响
10.Effectiveness and security of low molecular weight heparins on patients with cholestatic hepatitis
低分子肝素钠治疗淤胆型肝炎的研究